| 1 |
Massouh Skorin R, Escovar la Riva P, Gabler F, Kirmayr M, Khamis T, Escobar S, Díaz A, Soto L. Expression of PD-L1 in renal cancer, prognostic features and clinical utility of its routine staining. Actas Urol Esp (Engl Ed) 2023:S2173-5786(23)00006-9. [PMID: 36737036 DOI: 10.1016/j.acuroe.2022.12.005] [Reference Citation Analysis]
|
| 2 |
Massouh Skorin R, Escovar la Riva P, Gabler F, Kirmayr M, Khamis T, Escobar S, Díaz A, Soto L. Expresión de PD-L1 en cáncer renal, características pronósticas y utilidad en la práctica clínica habitual. Actas Urológicas Españolas 2023. [DOI: 10.1016/j.acuro.2022.12.002] [Reference Citation Analysis]
|
| 3 |
John A, Spain L, Hamid AA. Navigating the Current Landscape of Non-Clear Cell Renal Cell Carcinoma: A Review of the Literature. Curr Oncol 2023;30:923-37. [PMID: 36661719 DOI: 10.3390/curroncol30010070] [Reference Citation Analysis]
|
| 4 |
Rizzo A, Racca M, Dall'Armellina S, Rescigno P, Banna GL, Albano D, Dondi F, Bertagna F, Annunziata S, Treglia G. The Emerging Role of PET/CT with PSMA-Targeting Radiopharmaceuticals in Clear Cell Renal Cancer: An Updated Systematic Review. Cancers (Basel) 2023;15. [PMID: 36672305 DOI: 10.3390/cancers15020355] [Reference Citation Analysis]
|
| 5 |
Prakoso YA, Widyarini S, Faresy FC, Utomo YS. Clinicopathological study of sarcomatoid renal cell carcinoma in animals in East Java, Indonesia, from 2017 to 2022. Open Vet J 2023;13:64-73. [PMID: 36777435 DOI: 10.5455/OVJ.2023.v13.i1.7] [Reference Citation Analysis]
|
| 6 |
Xu W, Anwaier A, Liu W, Wei G, Su J, Tian X, Xia J, Qu Y, Zhao J, Zhang H, Ye D. Genomic alteration of MTAP/CDKN2A predicts sarcomatoid differentiation and poor prognosis and modulates response to immune checkpoint blockade in renal cell carcinoma. Front Immunol 2022;13:953721. [DOI: 10.3389/fimmu.2022.953721] [Reference Citation Analysis]
|
| 7 |
Yu Y, Wang Y, Wu Q, Zhao X, Liu D, Zhao Y, Li Y, Wang G, Xu J, Chen J, Zhang N, Tian X. Case Report and Systematic Review: Sarcomatoid Parathyroid Carcinoma-A Rare, Highly Malignant Subtype. Front Endocrinol (Lausanne) 2021;12:793718. [PMID: 34975762 DOI: 10.3389/fendo.2021.793718] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 8 |
Wang J, Zhanghuang C, Tan X, Mi T, Liu J, Jin L, Li M, Zhang Z, He D. Development and Validation of a Nomogram to Predict Distant Metastasis in Elderly Patients With Renal Cell Carcinoma. Front Public Health 2022;9:831940. [DOI: 10.3389/fpubh.2021.831940] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 9 |
Quhal F, Mori K, Fajkovic H, Remzi M, Shariat SF, Schmidinger M. Immunotherapy-based combinations in the first-line treatment of metastatic renal cell carcinoma with sarcomatoid features: a systematic review and network meta-analysis. Curr Opin Urol 2022;32:61-8. [PMID: 34720102 DOI: 10.1097/MOU.0000000000000940] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 10 |
Ranjan SK, Mittal A, Kumar S, Kishore S, Narain TA, Mammen KJ. Papillary Renal Cell Carcinoma with Sarcomatoid Differentiation in a Native Kidney of Transplant Recipient: A Case Report and Review of Literature. Indian J Nephrol 2021;31:386-9. [PMID: 34584356 DOI: 10.4103/ijn.IJN_239_20] [Reference Citation Analysis]
|
| 11 |
Barth DA, Sareban N, Lindner AK, Daller LAJ, Matzhold EM, Hutterer G, Smolle M, Mischinger J, Riedl JM, Seles M, Mannweiler S, Bauernhofer T, Pummer K, Pichler R, Zigeuner R, Schlenke P, Pichler M. Prognostic relevance of ABO blood group system in non-metastatic renal cell carcinoma: An analysis of two independent European cohorts with long-term follow-up. Urol Oncol 2021:S1078-1439(21)00264-7. [PMID: 34247906 DOI: 10.1016/j.urolonc.2021.06.005] [Reference Citation Analysis]
|
| 12 |
Yang J, Wang J, Liang Y, Wang J, Hsu J, Liu G, Li X, Tang Z, Zhang J, Huang Y, Yuan H, Chen Y. ATR and BRCA2 Simultaneous Mutation in a ccRCC With Sarcomatoid Differentiation and Extensive Metastases: A Case Report. Urology 2021;154:45-9. [PMID: 33961890 DOI: 10.1016/j.urology.2021.04.025] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 13 |
Sati N, Boyne DJ, Cheung WY, Cash SB, Arora P. Factors Modifying the Associations of Single or Combination Programmed Cell Death 1 and Programmed Cell Death Ligand 1 Inhibitor Therapies With Survival Outcomes in Patients With Metastatic Clear Cell Renal Cell Carcinoma: A Systematic Review and Meta-analysis. JAMA Netw Open 2021;4:e2034201. [PMID: 33496794 DOI: 10.1001/jamanetworkopen.2020.34201] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 14 |
Miller K, Bergmann L, Doehn C, Grünwald V, Gschwend JE, Ivanyi P, Keilholz U, Kuczyk MA. [Interdisciplinary recommendations for the treatment of advanced metastatic renal cell carcinoma]. Aktuelle Urol 2020;51:572-81. [PMID: 33027832 DOI: 10.1055/a-1252-1780] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 15 |
Chahoud J, Msaouel P, Ross JA, McCormick BZ, Bathala TK, Gao J, Horn R, Xiao L, Sircar K, Campbell MT, Shah AY, Goswami S, Zurita AJ, Jonasch E, Matin SF, Wood CG, Karam JA, Sharma P, Tannir NM. Outcomes of patients with metastatic renal cell carcinoma with sarcomatoid dedifferentiation to immune checkpoint inhibitors. Urol Oncol 2021;39:134.e9-134.e16. [PMID: 33187886 DOI: 10.1016/j.urolonc.2020.10.019] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 16 |
Attalla K, Voss MH, Hakimi AA. Prognostic models in papillary renal cell carcinoma. Ann Transl Med 2020;8:1334. [PMID: 33313079 DOI: 10.21037/atm-20-3750] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 17 |
Junker K, Eckstein M, Fiorentino M, Montironi R. PD1/PD-L1 Axis in Uro-oncology. Curr Drug Targets 2020;21:1293-300. [PMID: 32213156 DOI: 10.2174/1389450121666200326123700] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 18 |
Nahouraii LM, Allen JL, Merrill SB, Lehman E, Kaag MG, Raman JD. Histologic Heterogeneity of Extirpated Renal Cell Carcinoma Specimens: Implications for Renal Mass Biopsy. J Kidney Cancer VHL 2020;7:20-5. [PMID: 32953423 DOI: 10.15586/jkcvhl.2020.134] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 19 |
Gan CL, Dudani S, Heng DYC. Prognostic and Predictive Factors in Metastatic Renal Cell Carcinoma: Current Perspective and a Look Into the Future. Cancer J 2020;26:365-75. [PMID: 32947304 DOI: 10.1097/PPO.0000000000000468] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 20 |
Çetinarslan T, Ermertcan AT, Temiz P, Evrenos MK, Müezzinoğlu T. Dermoscopy of scalp cutaneous metastasis of sarcomatoid renal cell carcinoma. Dermatol Ther 2020;33:e14189. [PMID: 32794299 DOI: 10.1111/dth.14189] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 21 |
Thouvenin J, Barthélémy P, Ladoire S. Les cancers du rein non à cellules claires : caractéristiques clinico-biologiques et prise en charge thérapeutique hors chirurgie. Bulletin du Cancer 2020;107:S56-65. [DOI: 10.1016/s0007-4551(20)30279-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 22 |
Zhao Y, Chen H, Xie Y, Zhang C, Hou Y, Jin M. Clinicopathologic features and prognostic factors in patients with renal cell carcinoma with sarcomatoid differentiation. APMIS 2020;128:378-86. [PMID: 32048364 DOI: 10.1111/apm.13035] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 23 |
Manini C, López JI. The Labyrinth of Renal Cell Carcinoma. Cancers (Basel) 2020;12:E521. [PMID: 32102400 DOI: 10.3390/cancers12020521] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 24 |
Adashek JJ, Genovese G, Tannir NM, Msaouel P. Recent advancements in the treatment of metastatic clear cell renal cell carcinoma: A review of the evidence using second-generation p-values. Cancer Treatment and Research Communications 2020;23:100166. [DOI: 10.1016/j.ctarc.2020.100166] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 5.7] [Reference Citation Analysis]
|
| 25 |
Massari F, Nunno VD, Mollica V, Montironi R, Cheng L, Cimadamore A, Blanca A, Lopez-Beltran A. Immunotherapy in renal cell carcinoma from poverty to the spoiled of choice. Immunotherapy 2019;11:1507-21. [PMID: 31663411 DOI: 10.2217/imt-2019-0115] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
|
